Wall Street analysts expect that Avrobio Inc (NASDAQ:AVRO) will report earnings per share of ($0.76) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Avrobio’s earnings. The highest EPS estimate is ($0.70) and the lowest is ($0.78). Avrobio posted earnings of ($2.98) per share in the same quarter last year, which suggests a positive year over year growth rate of 74.5%. The business is expected to issue its next earnings results on Thursday, August 8th.
According to Zacks, analysts expect that Avrobio will report full-year earnings of ($2.93) per share for the current financial year, with EPS estimates ranging from ($3.12) to ($2.54). For the next financial year, analysts forecast that the business will post earnings of ($3.07) per share, with EPS estimates ranging from ($3.45) to ($2.65). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Avrobio.
Avrobio (NASDAQ:AVRO) last released its earnings results on Monday, May 13th. The company reported ($0.72) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.71) by ($0.01).
AVRO has been the subject of a number of recent analyst reports. HC Wainwright set a $40.00 price target on Avrobio and gave the stock a “buy” rating in a report on Tuesday, March 26th. Cowen reaffirmed a “buy” rating on shares of Avrobio in a report on Thursday, May 2nd. Janney Montgomery Scott assumed coverage on Avrobio in a report on Friday, April 5th. They set a “buy” rating and a $24.42 price target for the company. Finally, Mizuho assumed coverage on Avrobio in a report on Wednesday. They issued a “buy” rating and a $28.00 target price for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $30.68.
In related news, Director Christopher Paige sold 10,000 shares of the business’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $25.72, for a total value of $257,200.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Geoffrey Mackay sold 14,000 shares of the business’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $27.25, for a total value of $381,500.00. The disclosure for this sale can be found here. 4.70% of the stock is currently owned by insiders.
A number of hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its position in Avrobio by 90.8% in the 1st quarter. JPMorgan Chase & Co. now owns 1,224,455 shares of the company’s stock valued at $26,999,000 after acquiring an additional 582,639 shares during the period. Aisling Capital Management LP increased its position in Avrobio by 10.2% during the 1st quarter. Aisling Capital Management LP now owns 811,998 shares of the company’s stock worth $17,905,000 after purchasing an additional 75,000 shares during the period. BlackRock Inc. increased its position in Avrobio by 73.4% during the 4th quarter. BlackRock Inc. now owns 651,959 shares of the company’s stock worth $10,854,000 after purchasing an additional 276,018 shares during the period. Emerald Advisers LLC increased its position in Avrobio by 61.4% during the 1st quarter. Emerald Advisers LLC now owns 614,408 shares of the company’s stock worth $13,548,000 after purchasing an additional 233,772 shares during the period. Finally, Emerald Mutual Fund Advisers Trust increased its position in Avrobio by 40.2% during the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 522,590 shares of the company’s stock worth $11,523,000 after purchasing an additional 149,725 shares during the period. Hedge funds and other institutional investors own 71.13% of the company’s stock.
AVRO traded up $0.98 on Thursday, hitting $15.36. 280,323 shares of the company were exchanged, compared to its average volume of 164,201. Avrobio has a twelve month low of $11.85 and a twelve month high of $53.70. The stock has a market capitalization of $374.52 million and a P/E ratio of -4.25. The business has a 50-day moving average price of $15.78.
AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease.
Read More: Why is the LIBOR significant?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.